These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Tadalafil and patients preference in the treatment of erectile dysfunction].
    Author: Hu JL, Chen B.
    Journal: Zhonghua Nan Ke Xue; 2006 Dec; 12(12):1145-8. PubMed ID: 17201266.
    Abstract:
    ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
    [Abstract] [Full Text] [Related] [New Search]